miRNA‐128 and miRNA‐223 regulate cholesterol‐mediated drug resistance in breast cancer

Abstract

AbstractBackgroundBreast cancer is the second most common malignancy worldwide and 70% of all breast cancer cases are estrogen receptor‐positive (ER+). Endocrine therapy, Tamoxifen (TAM), is a popular treatment for ER+ breast cancer patients; however, despite its success in reducing breast cancer mortality, cancer drug resistance remains a significant challenge. A major contributor to this resistance is the dysregulation of cholesterol homeostasis, where breast cancer cells have elevated cholesterol levels. MicroRNAs (miRNAs) are master regulators of cholesterol‐related and cancer drug resistance pathways, and their aberrant expression often confers resistance. Therefore, we aimed to investigate the roles of miRNA‐128 and miRNA‐223 in cholesterol‐mediated TAM resistance.MethodsThree breast cancer cell lines were treated with a combination of 1 μM TAM and 10 μM of a cholesterol depleting agent (Acetyl Plumbagin: AP) following transfection with a miR‐128 inhibitor or a miR‐223 mimic. Cell viability and cholesterol levels were assessed using an MTT assay and fluorescence staining, respectively. In addition, expression levels of several genes and proteins involved in cancer drug resistance and cholesterol homeostasis were also assessed using RT‐qPCR and western blotting.ResultsThe combination treatment with altered miRNA expression led to reduced cell viability due to a reduction in free cholesterol and lipid rafts in MCF‐7, MDA‐MB‐231, and long‐term estrogen‐deprived cells (resistant breast cancer cells). Moreover, reduced miR‐128 expression was favoured in all breast cancer cell lines as this alteration lowered the expression of genes involved in cholesterol synthesis and transport, drug resistance, and cell signalling.ConclusionsInvestigating the gene expression profiles in different breast cancer cell lines was important to elucidate further the molecular mechanisms involved in miRNA‐regulated cholesterol homeostasis and cancer drug resistance. Therefore, our findings demonstrated that miR‐128 and miR‐223 could be potential targets in reducing TAM resistance through the depletion of excess cholesterol.